Summit Therapeutics (SMMT) earnings, Nov 4, 2026: EPS +16%, stock +2.3%
In brief
Summit Therapeutics reported on Nov 4, 2026. Earnings per share changed +16% year over year, 7.7% above the estimate; revenue 0%. The stock opened with a +2.2% gap and closed the day +2.3% (Nov 4, 2026). The stock is now 51.5% below its 52-week high, −21.5% over 12 months. Next report: Mar 18, 2027.
EPS vs estimate+7.7%
EPS, YoY+16%
Revenue, YoY0%
Gap · day+2.2% · +2.3%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Jul 23, 2026 | −8.4% | −8.8% |
| Nov 4, 2026 | +2.2% | +2.3% |
Next-quarter estimates, ratings and the SMMT chart are in the terminal.
Open the terminalFAQ
When is Summit Therapeutics's next earnings report?
Mar 18, 2027. The date comes from daily data and is corrected if the company moves it.
How did Summit Therapeutics stock react to the report?
Opening gap +2.2%, day's result +2.3%.
Did Summit Therapeutics's earnings grow?
Earnings per share rose 16% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.